Docoh
Loading...

TTNP Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Company profile

Ticker
TTNP, TTNPW
Exchange
CEO
Sunil Bhonsle
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
943171940

TTNP stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 May 21
29 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 11.63M 11.63M 11.63M 11.63M 11.63M 11.63M
Cash burn (monthly) (positive/no burn) (positive/no burn) 877.33K 479.83K 875K 1.22M
Cash used (since last report) n/a n/a 3.47M 1.9M 3.46M 4.82M
Cash remaining n/a n/a 8.16M 9.73M 8.16M 6.81M
Runway (months of cash) n/a n/a 9.3 20.3 9.3 5.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Feb 21 Marc Rubin Option to Purchase Common Stock Common Stock Grant Aquire A No No 4.02 150,000 603K 150,000
10 Feb 21 James R Mcnab Option to Purchase Common Stock Common Stock Grant Aquire A No No 4.02 25,000 100.5K 25,000
10 Feb 21 M David Macfarlane Option to Purchase Common Stock Common Stock Grant Aquire A No No 4.02 25,000 100.5K 25,000
10 Feb 21 Joseph A Akers Option to Purchase Common Stock Common Stock Grant Aquire A No No 4.02 25,000 100.5K 25,000
10 Feb 21 Katherine Beebe Option to Purchase Common Stock Common Stock Grant Aquire A No No 4.02 150,000 603K 150,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

24.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 28 22 +27.3%
Opened positions 8 5 +60.0%
Closed positions 2 4 -50.0%
Increased positions 7 1 +600.0%
Reduced positions 3 15 -80.0%
13F shares
Current Prev Q Change
Total value 7.47M 12.72M -41.3%
Total shares 2.38M 372.18K +539.4%
Total puts 126.8K 14.1K +799.3%
Total calls 227.5K 59.3K +283.6%
Total put/call ratio 0.6 0.2 +134.4%
Largest owners
Shares Value Change
Empery Asset Management 681.25K $2.16M NEW
Sabby Management 681.25K $2.16M +199.4%
L1 Capital Global Opportunities Master Fund 681.25K $2.16M NEW
Group One Trading 73.11K $218K +8971.1%
Vanguard 72.79K $217K +28.4%
Gsa Capital Partners 39.82K $119K NEW
Geode Capital Management 35.52K $105K +0.0%
UBS UBS Group AG - Registered Shares 23.46K $70K +287.0%
CS Credit Suisse 23.2K $69K NEW
Citadel Advisors 19.28K $57K -14.4%
Largest transactions
Shares Bought/sold Change
Empery Asset Management 681.25K +681.25K NEW
L1 Capital Global Opportunities Master Fund 681.25K +681.25K NEW
Sabby Management 681.25K +453.7K +199.4%
Group One Trading 73.11K +72.31K +8971.1%
Gsa Capital Partners 39.82K +39.82K NEW
CS Credit Suisse 23.2K +23.2K NEW
BK Bank Of New York Mellon 18.2K +18.2K NEW
UBS UBS Group AG - Registered Shares 23.46K +17.4K +287.0%
Millennium Management 16.88K +16.88K NEW
Vanguard 72.79K +16.1K +28.4%

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Abuse, accredited, accuracy, accurate, acute, attack, attempted, basic, begin, beginning, belief, breach, caution, classification, competition, compromise, computer, computing, Cybersecurity, damage, deployment, destruction, detect, disappointing, DPT, drawn, embedded, employing, engineering, entity, enumerated, expose, exposed, faith, fiscal, format, fourth, frequency, guarantee, harm, harmful, high, hope, human, inadequate, increasingly, ineffective, inference, infrastructure, integrity, intensity, interruption, intrusion, involve, Jr, malware, mice, move, multifactorial, nasally, posture, potency, random, ratio, recast, reliability, reputation, reputational, resale, retroactive, retrospective, sensitive, shorter, shortfall, side, speak, streamlined, submission, suggested, terminology, thirty, threaten, unauthorized, undesirable, undue, vulnerable, whistleblower
Removed: accreted, amortized, analyze, anniversary, anticipated, apparent, arm, arriving, authorization, base, bear, Bhonsle, calculate, carrying, Chief, compliance, constitute, continuously, correct, coupon, coverage, delayed, digital, discount, disease, downturn, elimination, enterprise, established, extinguish, extinguishment, floating, floor, fully, gain, global, highly, limitation, litigation, local, making, manufacturer, medication, meet, mitigate, modification, modify, monthly, OUD, pandemic, pay, phase, prepayment, President, ProNeuraTM, prove, quarantine, reacquire, reduced, reflected, reimbursement, relevant, repay, repayable, Repayment, reserved, rod, scheduled, shelter, significantly, spread, stage, sustained, territory, tranche, transmission, unpaid, upper